Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2901858 | 0.89 | GAA (0.63) | GAATSHRALDH1A1POLBTP53 | |
| SCHEMBL2905024 | 0.87 | GAA (0.58) | GAATSHRALDH1A1MAPTLMNA | |
| SCHEMBL2902341 | 0.83 | GAA (0.58) | GAATSHRPOLBKCNH2TP53 | |
| SCHEMBL2907150 | 0.80 | GAA (0.55) | GAATSHRPOLBTP53MAPT | |
| SCHEMBL13886050 | 0.79 | GAA (0.54) | GAATSHRALDH1A1POLBTP53 | |
| SCHEMBL2901399 | 0.77 | GAA (0.56) | GAATSHRALDH1A1POLBMAPT | |
| SCHEMBL2907735 | 0.75 | GAA (0.54) | GAATSHRALDH1A1POLBMAPT | |
| SCHEMBL2908982 | 0.74 | GAA (0.53) | GAATSHRALDH1A1POLBMAPT | |
| SCHEMBL2905932 | 0.73 | GAA (0.52) | GAATSHRALDH1A1MAPTRAB9A | |
| SCHEMBL2902665 | 0.71 | GAA (0.49) | GAATSHRALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874761-B1 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | claimed |
| EP-1874761-B1 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | disclosed |
| US-7517881-B2 | Triazine derivatives, their preparation and therapeutic application thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-7517881-B2 | Triazine derivatives, their preparation and therapeutic application thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-7517881-B2 | Triazine derivatives, their preparation and therapeutic application thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-04-24 | — | — | US | disclosed |
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-04-24 | — | — | US | disclosed |
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-04-24 | — | — | US | disclosed |
| EP-1874761-A2 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | Aventis Pharma S.A. (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111662-A2 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | AVENTIS PHARMA S.A. (FR) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | CYP11B2, IL5, TBXA2R | GAA 1439/4885TSHR 26/4885ALDH1A1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.